Oncopeptides (Sweden) Today
| ONCO Stock | SEK 1.44 0.03 2.13% |
Performance0 of 100
| Odds Of DistressOver 84
|
Oncopeptides is selling for under 1.44 as of the 31st of January 2025; that is 2.13 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.41. Oncopeptides has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 3rd of September 2024 and ending today, the 31st of January 2025. Click here to learn more.
Oncopeptides AB , a pharmaceutical company, develops drugs for the treatment of cancer. The company was founded in 2000 and is headquartered in Stockholm, Sweden. Oncopeptides is traded on Stockholm Stock Exchange in Sweden. The company has 90.37 M outstanding shares. More on Oncopeptides AB
Moving together with Oncopeptides Stock
Moving against Oncopeptides Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Oncopeptides Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Oncopeptides' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Oncopeptides or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Oncopeptides AB (ONCO) is traded on Stockholm Exchange in Sweden and employs 40 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 933.96 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oncopeptides's market, we take the total number of its shares issued and multiply it by Oncopeptides's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Oncopeptides AB operates under Biotechnology sector and is part of Health Care industry. The entity has 90.37 M outstanding shares.
Oncopeptides AB has accumulated about 747.47 M in cash with (1.52 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.3, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Oncopeptides Probability Of Bankruptcy
Ownership AllocationOncopeptides owns a total of 90.37 Million outstanding shares. 30% of Oncopeptides AB outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Oncopeptides Ownership Details
Oncopeptides AB Risk Profiles
Although Oncopeptides' alpha and beta are two of the key measurements used to evaluate Oncopeptides' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.36 | |||
| Standard Deviation | 4.04 | |||
| Variance | 16.31 | |||
| Risk Adjusted Performance | (0.09) |
Oncopeptides Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Oncopeptides without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Optimizer Now
Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
| All Next | Launch Module |
Oncopeptides Corporate Management
Elected by the shareholders, the Oncopeptides' board of directors comprises two types of representatives: Oncopeptides inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncopeptides. The board's role is to monitor Oncopeptides' management team and ensure that shareholders' interests are well served. Oncopeptides' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncopeptides' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Annika MBA | Interim Officer | Profile | |
| Kristina Luthman | Founder | Profile | |
| Linda Holmstrom | Director Relations | Profile | |
| Peter Nygren | Founder | Profile | |
| Pr MD | Founder | Profile | |
| Jakob Lic | Chief Officer | Profile | |
| MSc MD | Founder | Profile |
Additional Tools for Oncopeptides Stock Analysis
When running Oncopeptides' price analysis, check to measure Oncopeptides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncopeptides is operating at the current time. Most of Oncopeptides' value examination focuses on studying past and present price action to predict the probability of Oncopeptides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncopeptides' price. Additionally, you may evaluate how the addition of Oncopeptides to your portfolios can decrease your overall portfolio volatility.